Land: Sverige
Språk: svenska
Källa: Läkemedelsverket (Medical Products Agency)
influensavirus A/Brisbane/10/2007 (H3N2)-liknande stam (A/Uruguay/716/2007, NYMC X-175C), ytantigen, inaktiverat; influensavirus A/Brisbane/59/2007 (H1N1)-liknande stam (A/Brisbane/59/2007, IVR-148), ytantigen, inaktiverat; influensavirus B/Brisbane/60/2008-liknande stam (B/Brisbane/60/2008), ytantigen, inaktiverat
Sanofi Pasteur MSD S.p.A.
J07BB02
the influenza virus, A/Brisbane/10/2007 (H3N2)-like strain (A/Uruguay/716/2007, NYMC X-175C), surface antigen, inactivated; influenza virus, A/Brisbane/59/2007 (H1N1)-like strain (A/Brisbane/59/2007, IVR-148), surface antigen, inactivated; influenza virus, B/Brisbane/60/2008-like strain (B/Brisbane/60/2008), the surface antigen, inactivated
Injektionsvätska, suspension i emulsion i förfylld spruta
skvalan 9,75 mg Adjuvans; citronsyra (vattenfri) 0,04 mg Adjuvans; natriumcitrat (dihydrat) 0,66 mg Adjuvans; sorbitantrioleat 1,175 mg Adjuvans; influensavirus B/Brisbane/60/2008-liknande stam (B/Brisbane/60/2008), ytantigen, inaktiverat 15 mikrog Aktiv substans; influensavirus A/Brisbane/10/2007 (H3N2)-liknande stam (A/Uruguay/716/2007, NYMC X-175C), ytantigen, inaktiverat 15 mikrog Aktiv substans; polysorbat 80 1,175 mg Adjuvans; influensavirus A/Brisbane/59/2007 (H1N1)-liknande stam (A/Brisbane/59/2007, IVR-148), ytantigen, inaktiverat 15 mikrog Aktiv substans
Receptbelagt
spjälkat virus eller ytantigen
Avregistrerad
2000-08-25